ClinicalTrials.gg
RecruitingNCT05702229Updated May 14, 2026

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of Rilvegostomig and Volrustomig in Gastric Cancer, sponsored by AstraZeneca. Recruiting at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
163
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Planned enrollment
12th of 27
163 · median 124
Started
2023
with 2 others
Phase 2
9 of 30
4 open now
Primary completion
2027-11
later than 10 of 17 live
Registered
18th of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2023, is one of 9 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 18th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Read the detailed description

Approximately 360 participants will be assigned across 4 substudies, with approximately 60 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy/cohort.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Locally advanced
  • Metatstatic
  • Gastric adenocarcinoma
  • GEJ adenocarcinoma
  • GEMINI-Gastric
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older at the time of signing the ICF.
  • Body weight > 35 kg.
  • Previously untreated for unresectable or gastric or gastroesophageal junction adenocarcinoma.
  • Has measurable target disease assessed by the Investigator based on 1.1.
  • PS zero or one.
  • of at least 12 weeks.
  • Adequate organ and bone marrow function.
  • Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh when Substudy 3, Substudy 4 i s open for recruitment.

Exclusion criteria

Exclusion Criteria:

  • Participants with -positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
  • Untreated or progressive CNS disease, any , or cord compression.
  • Participants with ascites which cannot be controlled with appropriate interventions.
  • Active infectious diseases, including tuberculosis, infection, or /C.
  • Uncontrolled intercurrent illness.
  • Active or prior documented or inflammatory disorders requiring systemic treatment with or other treatment.
  • History of another primary .
  • Previous treatment with an immune-oncology agent.
  • Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
163 participants (estimated)

Study arms

  • Experimental
    Substudy 1

    Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)

    Drug: Volrustomig · Drug: FOLFOX · Drug: XELOX

  • Experimental
    Substudy 2

    Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)

    Drug: Rilvegostomig · Drug: FOLFOX · Drug: XELOX

  • Experimental
    Substudy 3

    AZD0901 plus volrustomig and 5-fluorouracil or capecitabine

    Drug: Volrustomig · Drug: AZD0901 · Drug: 5-Fluorouracil · Drug: Capecitabine

  • Experimental
    Substudy 4, Cohort 4a1

    Sonesitatug vedotin (AZD0901) plus rilvegostomig and 5-fluorouracil or capecitabine

    Drug: Rilvegostomig · Drug: AZD0901 · Drug: 5-Fluorouracil · Drug: Capecitabine

  • Experimental
    Substudy 4, Cohort 4a2

    Sonesitatug vedotin (AZD0901) plus rilvegostomig and 5-fluorouracil

    Drug: Rilvegostomig · Drug: AZD0901 · Drug: 5-Fluorouracil

  • Experimental
    Substudy 4, Cohort 4b

    Sonesitatug vedotin (AZD0901) plus capecitabine

    Drug: AZD0901 · Drug: Capecitabine

Interventions

  • an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion

  • an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

  • DrugFOLFOX

    5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)

  • DrugXELOX

    capecitabine and oxaliplatin

  • an anti Claudin18.2 ADC; IV infusion

  • 5-FU, IV infusion

  • Oral take

06

What researchers measure

Primary outcomes

  1. ORR (per RECIST 1.1 as assessed by Investigator)

    the proportion of participants who have a confirmed complete response or confirmed partial response, as determined by the Investigator at local site per RECIST 1.1.

    Time frame: Through substudy completion, an average of 2 years

  2. PFS6 (per RECIST 1.1 as assessed by Investigator)

    the proportion of participants alive and progression-free at 6 months.

    Time frame: Through substudy completion, an average of 2 years

Secondary outcomes

  1. PFS per RECIST 1.1 as assessed by the Investigator

    the time from the start of study intervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression.

    Time frame: Through substudy completion, an average of 2 years

  2. OS

    the time from the start of study intervention until the date of death due to any cause.

    Time frame: Through substudy completion, an average of 2 years

  3. other safety related endpoints

    Incidence of AEs, AESIs, and SAEs.

    Time frame: Through substudy completion, an average of 2 years

  4. DoR per RECIST 1.1 based on Investigator assessment.

    the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 by the Investigator at local site or death due to any cause in the absence of disease progression.

    Time frame: Through substudy completion, an average of 2 years

07

Study locations

35 of 44 sites recruiting
  • Research Site
    Los Angeles, California 90017, United States
    Recruiting
  • Research Site
    Los Angeles, California 90095, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Baton Rouge, Louisiana 70817, United States
    Recruiting
  • Research Site
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • Research Site
    New Hyde Park, New York 11042, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10028, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    New York, New York 11210, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Shirley, New York 11967, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    The Bronx, New York 10469, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Hangzhou, 310003, China
    Recruiting
  • Research Site
    Hangzhou, 310020, China
    Recruiting
  • Research Site
    Harbin, 150081, China
    Recruiting
  • Research Site
    Hefei, 230031, China
    Recruiting
  • Research Site
    Kunming, 650118, China
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Wuhan, 430079, China
    Recruiting
  • Research Site
    Yinchuan, 750004, China
    Recruiting
  • Research Site
    Zhengzhou, 450052, China
    Recruiting
  • Research Site
    Chūōku, 104-0045, Japan
    Recruiting
  • Research Site
    Kashiwa, 227-8577, Japan
    Recruiting
  • Research Site
    Sunto-gun, 411-8777, Japan
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 03722, South Korea
    Recruiting
  • Research Site
    Seoul, 05505, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Barcelona, 08035, Spain
    Recruiting
  • Research Site
    Elche(Alicante), 03202, Spain
    Recruiting
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
    Recruiting
  • Research Site
    Madrid, 28007, Spain
    Recruiting
  • Research Site
    Madrid, 28040, Spain
    Recruiting
  • Research Site
    Santander, 39008, Spain
    Recruiting
  • Research Site
    Hsinchu, 300, Taiwan
    Recruiting
  • Research Site
    Kaohsiung City, 80756, Taiwan
    Recruiting
  • Research Site
    Taichung, 404, Taiwan
    Recruiting
  • Research Site
    Tainan, 70403, Taiwan
    Recruiting
  • Research Site
    Taipei, 10002, Taiwan
    Recruiting
  • Research Site
    Taipei, 11259, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 333, Taiwan
    Recruiting
  • Research Site
    Edinburgh, EH4 2XU, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Leeds, LS9 7TF, United Kingdom
    Recruiting
  • Research Site
    London, EC1M 6BQ, United Kingdom
    Recruiting
  • Research Site
    Oxford, OX3 7LE, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Nov 2027, 58 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 58 months is above that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Jan 27, 2023
StartActual
Jan 16, 2023
Primary completionEst.
Nov 30, 2027
CompletionEst.
May 31, 2029
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05702229
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Jan 16, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
May 31, 2029 (estimated)
Last update
May 14, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rilvegostomig · Volrustomig · Folfox protocol · Xelox · Sonesitatug vedotin

Start the discussion